Barboval

A drug that affects the central nervous system. Let's get acquainted with its instructions, indications for use, dosage and side effects. Barboval belongs to the pharmacological category of sedative and hypnotic drugs. It has a combined composition, which provides a sedative, hypotensive and antispasmodic effect. Relaxes smooth muscles and reduces flatulence. It contains phenobarbital, which has a vasodilatory and sedative effect. The antispasmodic effect is caused by the action of ethyl ester of α-bromisovaleric acid.

Indications Barboval

Barboval is prescribed for the treatment of central nervous system disorders. This is due to its calming, vasodilatory and antispasmodic effects.

Indications for use:

• Insomnia
• Neuroses
• Hysteria
• Irritability
• Sinus tachycardia
• Arterial hypertension stage I
• Attacks of angina pectoris (mild)
• Spasms of the intestines and stomach
• Flatulence

The medication helps to slow down intestinal and gastric peristalsis, reduces flatulence and has a relaxing effect on the muscular system.

Release form

The sedative is available in the form of drops in 25 ml, 30 ml and 50 ml bottles and in the form of hard gelatin capsules. These forms of release allow you to calculate the amount of medicine required for treatment.

• 1 ml Barboval contains: 17 mg phenobarbital, 80 mg liquid validol, 18 mg ethyl ester of alpha-bromisovaleric acid. Excipients: sodium acetate trihydrate, rectified ethyl alcohol and purified water.
• 1 capsule contains: 10 mg of ethyl ester of α-bromisovaleric acid, 9.8 mg of phenobarbital, 46 mg of menthol solution in menthyl ester of isovaleric acid. Excipients: lactose, castor oil, calcium stearate, microcrystalline cellulose, colloidal silicon dioxide and crospovidone.

Pharmacodynamics

The therapeutic effect of the drug is due to its combined composition. Pharmacodynamics is represented by the following substances:

• Phenobarbital - enhances the sedative effect of other components, reduces the level of CNS excitation and restores sleep patterns. Reduces blood pressure, pathological effects on vasomotor centers, peripheral and coronary vessels. Prevents and eliminates vascular spasms.
• Ethyl ether of a-bromisovaleric acid - has an antispasmodic, sedative and reflex action. These effects are due to irritation of the receptors of the oral cavity and nasopharynx, a decrease in the reflex excitability of the central nervous system and increased inhibition of processes in the subcortical structures and neurons of the brain. Reduces the activity of the central vasomotor centers, has an antispasmodic effect on smooth muscles.
• Levomenthol solution in menthyl isovalerate – has a moderate vasodilatory and sedative effect. This effect is caused by irritation of sensitive nerve endings. The substance slows down peristalsis of the gastrointestinal tract.

Pharmacokinetics

After oral administration, the drug is distributed throughout the body, exerting a therapeutic effect. Pharmacokinetics is based on the mechanism of action of its active components.

Barboval has a long-lasting soft effect. The active substances are quickly absorbed in the stomach, binding to blood proteins is 40-60%. The half-life is 2-6 days. Metabolism occurs in the liver, about 30% of the drug is excreted unchanged in the urine. With repeated use, the drug accumulates and is excreted from the body very slowly.

Dosing and administration

As a rule, Barboval is prescribed 10-15 drops or 1-2 capsules per dose. The medicine is taken 2-3 times a day, depending on the severity of the pathological symptoms requiring treatment. The method of administration and dosage can be adjusted depending on the therapeutic effect.

Drops should be taken 30-40 minutes before meals, dissolving in a glass of water or dripping onto a piece of sugar. Tablets are taken before meals, the maximum permissible number of capsules per day is 6 pieces. The duration of therapy is 10-14 days, a repeat course is carried out after a break of 1-2 weeks.

Use Barboval during pregnancy

For the treatment of nervous system disorders in women during pregnancy and lactation, it is recommended to use herbal sedatives. Barboval is contraindicated for use during pregnancy. This is due to the activity of its components, which can penetrate the placental barrier.

Contraindications

Barboval has certain contraindications for use. This applies to pediatric patients, pregnant women and breastfeeding women. The drug is not used in case of hypersensitivity to its active and auxiliary components.

Since Barboval contains phenobarbital, it can cause the development of Lyell's syndrome or Stevens-Johnson syndrome in the first days of treatment. Long-term therapy is a risk of developing drug dependence and bromine poisoning. With special caution, drops are prescribed to patients with arterial hypotension, acute and constant pain, decompensated heart failure, drug intoxication, adrenal hypofunction, hyperkinesis and hyperthyroidism.

Failure to follow these recommendations may result in adverse symptoms from the central nervous system and other body systems.

Side effects Barboval

The medication is well tolerated. Side effects are extremely rare and, as a rule, due to the use of high doses of drops. Patients may complain of attacks of nausea and vomiting, increased drowsiness, headaches and dizziness, lacrimation.

There is no specific antidote. Side effects disappear immediately after discontinuing the drug or reducing the dosage.

Overdose

The use of high doses or exceeding the course of treatment prescribed by the doctor causes symptoms of overdose. This is expressed as depression of psychomotor reactions, headaches, dizziness, increased sleepiness, general weakness, nausea and vomiting attacks.

Signs of overdose are relieved after reducing the dosage or stopping the drops/tablets. If the side effects are pronounced and there are signs of severe intoxication, it is recommended to take central nervous system stimulants (Ethimizole, Bemegride, Caffeine, etc.).

Interactions with other drugs

Barboval can be used in combination therapy of CNS disorders and other diseases. Interaction with other drugs is regulated by the attending physician. When used simultaneously with neuroleptics and tranquilizers, Barboval potentiates their effect. When combined with CNS stimulants, a decrease in the effectiveness of each of the drugs is observed.

The psycholeptic agent is not recommended for use with medications that are metabolized in the liver (indirect coagulants, antibiotics, sulfonamides). This is due to the action of phenobarbital, which induces microsomal enzymes and reduces the effectiveness of drugs. Alcohol enhances the effect of the sedative and increases its toxicity.

[ 1 ], [ 2 ]

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

[ 3 ]

Shelf life

Barboval must be used within 36 months from the date of manufacture (indicated on the bottle with drops and on the packaging of capsules). After this period, the medication is contraindicated for use and must be disposed of.